Does APALUTAMIDE Cause Malignant neoplasm progression? 40 Reports in FDA Database
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 40 reports of Malignant neoplasm progression have been filed in association with APALUTAMIDE (ERLEADA). This represents 0.4% of all adverse event reports for APALUTAMIDE.
40
Reports of Malignant neoplasm progression with APALUTAMIDE
0.4%
of all APALUTAMIDE reports
4
Deaths
3
Hospitalizations
How Dangerous Is Malignant neoplasm progression From APALUTAMIDE?
Of the 40 reports, 4 (10.0%) resulted in death, 3 (7.5%) required hospitalization.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for APALUTAMIDE. However, 40 reports have been filed with the FAERS database.
What Other Side Effects Does APALUTAMIDE Cause?
Rash (1,117)
Death (1,008)
Fatigue (824)
Hot flush (532)
Product dose omission issue (384)
Diarrhoea (317)
Asthenia (303)
Dizziness (294)
Fall (268)
Off label use (257)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which APALUTAMIDE Alternatives Have Lower Malignant neoplasm progression Risk?
APALUTAMIDE vs APATINIB
APALUTAMIDE vs APIDRA
APALUTAMIDE vs APIDRA SOLOSTAR
APALUTAMIDE vs APIXABAN
APALUTAMIDE vs APLISOL DIAGNOSTIC ANTIGEN